Human pathogenic hantaviruses and prevention of infection

Human Vaccines

Volumn 7, Issue 6, 2011, Pages 685-693

  Krüger, Detlev H ^a   Schönrich, Günther ^a   Klempa, Boris ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Hantavirus; Immunopathogenesis; Protective immunity; Vaccines

Indexed keywords

1 BETA DEXTRO RIBOFURANOSYL 3 ETHYNYL [1,2,4]TRIAZOLE; ANTIVIRUS AGENT; CYCLOPEPTIDE; DNA VACCINE; GAMMA INTERFERON; HANTAVAX; HLA B35 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; N' 3 FLUOROPHENYL INOSINE; PLACEBO; POLYCLONAL ANTIBODY; RECOMBINANT N PROTEIN; RECOMBINANT PROTEIN; RIBAVIRIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ANDES VIRUS; ANEMIA; ANTIVIRAL ACTIVITY; CARDIOPULMONARY INSUFFICIENCY; CD8+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE CARRIER; DRUG EFFICACY; DRUG TOLERABILITY; HANTAVIRUS; HANTAVIRUS INFECTION; HANTAVIRUS PULMONARY SYNDROME; HEMORRHAGIC FEVER WITH RENAL SYNDROME; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTE FUNCTION; NONHUMAN; PASSIVE IMMUNIZATION; PUUMALA VIRUS; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ADAPTIVE IMMUNITY; HANTAVIRUS; HANTAVIRUS INFECTIONS; HUMANS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 79959371873     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.6.15197     Document Type: Review

References (101)

1. Kruger DH, Ulrich R, Lundkvist AH. Hantavirus infections and their prevention. Microbes Infect 2001; 3:1129-44. (Pubitemid 33044739)
2. Lee HW, van der GG. Hemorrhagic fever with renal syndrome. Prog Med Virol 1989; 36:62-102.
3. Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis 2006; 19:437-42. (Pubitemid 44338102)
4. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 1999; 50:531-45. (Pubitemid 29117081)
5. Faber MS, Ulrich RG, Frank C, Brockmann SO, Pfaff GM, Jacob J, et al. Steep rise in notified hantavirus infections in Germany, April 2010. Euro Surveill 2010; 15.
6. Klempa B, Fichet-Calvet E, Lecompte E, Auste B, Aniskin V, Meisel H, et al. Hantavirus in African wood mouse, Guinea. Emerg Infect Dis 2006; 12:838-40.
7. Klempa B, Koivogui L, Sylla O, Koulemou K, Auste B, Kruger DH, ter Meulen J. Serological evidence of human hantavirus infections in Guinea, West Africa. J Infect Dis 2010; 201:1031-4.
8. Schmaljohn CS, Nichol ST. Bunyaviridae. In: Knipe DM and Howley PM, Eds. Fields Virology. Philadelphia: Lippencott Williams & Wilkins 2007; 5:1741-89.
9. Klempa B, Tkachenko EA, Dzagurova TK, Yunicheva YV, Morozov VG, Okulova NM, et al. Hemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia. Emerg Infect Dis 2008; 14:617-25. (Pubitemid 351520864)
10. Krüger DH, Klempa B. Dobrava-Belgrade Virus. In: Liu D, Ed. Molecular detection of human viral pathogens. Boca Raton: CRC Press 2011; 631-8.
11. Hooper JW, Ferro AM, Wahl-Jensen V. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J Virol 2008; 82:1332-8.
12. Hammerbeck CD, Wahl-Jensen V, Hooper JW. Hantavirus. In: Barrett ADT, Stanberry LR, Eds. Vaccines for biodefense and emerging and neglected diseases. London: Academic Press/Elsevier 2009; 379-412.
13. Chaparro J, Vega J, Terry W, Vera JL, Barra B, Meyer R, et al. Assessment of person-to-person transmission of hantavirus pulmonary syndrome in a Chilean hospital setting. J Hosp Infect 1998; 40:281-5. (Pubitemid 28552395)
14. Enria D, Padula P, Segura EL, Pini N, Edelstein A, Posse CR, Weissenbacher MC. Hantavirus pulmonary syndrome in Argentina. Possibility of person to person transmission. Medicina (B Aires) 1996; 56:709-11.
15. Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, et al. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis 2007; 195:1563-71. (Pubitemid 46799213)
16. Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula PJ. Person-to-person transmission of Andes virus. Emerg Infect Dis 2005; 11:1848-53. (Pubitemid 43356079)
17. Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998; 241:323-30. (Pubitemid 28384205)
18. Galeno H, Mora J, Villagra E, Fernandez J, Hernandez J, Mertz GJ, Ramirez E. First human isolate of Hantavirus (Andes virus) in the Americas. Emerg Infect Dis 2002; 8:657-61. (Pubitemid 34764728)
19. Muranyi W, Bahr U, Zeier M, van der Woude FJ. Hantavirus infection. J Am Soc Nephrol 2005; 16:3669-79. (Pubitemid 46211288)
20. Kariwa H, Yoshimatsu K, Arikawa J. Hantavirus infection in East Asia. Comp Immunol Microbiol Infect Dis 2007; 30:341-56. (Pubitemid 47450088)
21. Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology and disease. Clin Microbiol Rev 2010; 23:412-41.
22. Maes P, Klempa B, Clement J, Matthijnssens J, Gajdusek DC, Kruger DH, Van Ranst M. A proposal for new criteria for the classification of hantaviruses, based on S and M segment protein sequences. Infect Genet Evol 2009; 9:813-20.
23. Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA. Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. London: Elsevier Academic Press 2005.
24. Raftery MJ, Kraus AA, Ulrich R, Kruger DH, Schonrich G. Hantavirus infection of dendritic cells. J Virol 2002; 76:10724-33. (Pubitemid 35176189)
25. Leduc JW, Ksiazek TG, Rossi CA, Dalrymple JM. A retrospective analysis of sera collected by the Hemorrhagic Fever Commission during the Korean Conflict. J Infect Dis 1990; 162:1182-4. (Pubitemid 20353603)
26. Alexeyev OA, Ahlm C, Billheden J, Settergren B, Wadell G, Juto P. Elevated levels of total and Puumala virus-specific immunoglobulin E in the Scandinavian type of hemorrhagic fever with renal syndrome. Clin Diagn Lab Immunol 1994; 1:269-72. (Pubitemid 2085401)
27. Markotic A, Dasic G, Gagro A, Sabioncello A, Rabatic S, Kuzman I, et al. Role of peripheral blood mononuclear cell (PBMC) phenotype changes in the pathogenesis of haemorrhagic fever with renal syndrome (HFRS). Clin Exp Immunol 1999; 115:329-34.
28. Gott P, Zoller L, Darai G, Bautz EK. A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein. Virus Genes 1997; 14:31-40. (Pubitemid 27267514)
29. Kallio-Kokko H, Lundkvist A, Plyusnin A, Avsic-Zupanc T, Vaheri A, Vapalahti O. Antigenic properties and diagnostic potential of recombinant Dobrava virus nucleocapsid protein. J Med Virol 2000; 61:266-74. (Pubitemid 30257253)
30. Kallio-Kokko H, Leveelahti R, Brummer-Korvenkontio M, Lundkvist A, Vaheri A, Vapalahti O. Human immune response to Puumala virus glycoproteins and nucleocapsid protein expressed in mammalian cells. J Med Virol 2001; 65:605-13. (Pubitemid 32959091)
31. Lundkvist A, Bjorsten S, Niklasson B, Ahlborg N. Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus: definition of epitopes specific for acute immunoglobulin G recognition in humans. Clin Diagn Lab Immunol 1995; 2:82-6.
32. Lundkvist A, Kallio-Kokko H, Sjolander KB, Lankinen H, Niklasson B, Vaheri A, Vapalahti O. Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology 1996; 216:397-406. (Pubitemid 26083383)
33. Lundkvist A, Vapalahti O, Plyusnin A, Sjolander KB, Niklasson B, Vaheri A. Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed nucleocapsid protein. Virus Res 1996; 45:29-44. (Pubitemid 26316233)
34. Tischler ND, Galeno H, Rosemblatt M, Valenzuela PD. Human and rodent humoral immune responses to Andes virus structural proteins. Virology 2005; 334:319-26. (Pubitemid 40386966)
35. Zoller L, Scholz J, Stohwasser R, Giebel LB, Sethi KK, Bautz EK, Darai G. Immunoblot analysis of the serological response in Hantavirus infections. J Med Virol 1989; 27:231-7. (Pubitemid 19109445)
36. Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment and prevention. Viral Immunol 2004; 17:481-97.
37. Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch Virol 1993; 130:365-76.
38. Valdivieso F, Vial P, Ferres M, Ye C, Goade D, Cuiza A, Hjelle B. Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Emerg Infect Dis 2006; 12:166-8. (Pubitemid 43143558)
39. Ye C, Prescott J, Nofchissey R, Goade D, Hjelle B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis 2004; 10:478-82. (Pubitemid 38314475)
40. Horling J, Lundkvist A, Huggins JW, Niklasson B. Antibodies to Puumala virus in humans determined by neutralization test. J Virol Methods 1992; 39:139-47.
41. Lundkvist A, Horling J, Niklasson B. The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays. Arch Virol 1993; 130:121-30.
42. Manigold T, Mori A, Graumann R, Llop E, Simon V, Ferres M, et al. Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus. PLoS Pathog 2010; 6:1000779.
43. Chu YK, Jennings G, Schmaljohn A, Elgh F, Hjelle B, Lee HW, et al. Cross-neutralization of hantaviruses with immune sera from experimentally infected animals and from hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome patients. J Infect Dis 1995; 172:1581-4.
44. Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J Virol 2001; 75:8469-77. (Pubitemid 32768951)
45. Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol 2003; 77:9894-905. (Pubitemid 37122070)
46. Hooper JW, Custer DM, Smith J, Wahl-Jensen V. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 2006; 347:208-16.
47. de Carvalho NC, Gonzalez D, Padula PV, Bjorling E, Plyusnin A, Lundkvist A. Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. J Virol 2002; 76:6669-77. (Pubitemid 34633533)
48. Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000; 182:43-8. (Pubitemid 30497787)
49. MacNeil A, Comer JA, Ksiazek TG, Rollin PE. Sin Nombre virus-specific immunoglobulin M and G kinetics in hantavirus pulmonary syndrome and the role played by serologic responses in predicting disease outcome. J Infect Dis 2010; 202:242-6.
50. Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 1990; 64:3162-70. (Pubitemid 20219517)
51. Hooper JW, Kamrud KI, Elgh F, Custer D, Schmaljohn CS. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology 1999; 255:269-78. (Pubitemid 29393338)
52. Pensiero MN, Jennings GB, Schmaljohn CS, Hay J. Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol 1988; 62:696-702. (Pubitemid 18068623)
53. Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg 1992; 47:397-404.
54. Klingstrom J, Stoltz M, Hardestam J, Ahlm C, Lundkvist A. Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge. Antivir Ther 2008; 13:125-33. (Pubitemid 351541682)
55. Huang C, Jin B, Wang M, Li E, Sun C. Hemorrhagic fever with renal syndrome: relationship between pathogenesis and cellular immunity. J Infect Dis 1994; 169:868-70. (Pubitemid 24102122)
56. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol 2004; 172:3297-304. (Pubitemid 38263722)
57. Van Epps HL, Terajima M, Mustonen J, Arstila TP, Corey EA, Vaheri A, Ennis FA. Long-lived memory T lymphocyte responses after hantavirus infection. J Exp Med 2002; 196:579-88. (Pubitemid 35024437)
58. Van Epps HL, Schmaljohn CS, Ennis FA. Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. J Virol 1999; 73:5301-8. (Pubitemid 29274811)
59. Björkström NKL T, Stoltz M, Fauriat C, Braun M, Michaëlsson J, Klingström J, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011; 208: 13-21.
60. Wang PZ, Huang CX, Zhang Y, Li ZD, Yo HT, Zhang Y, et al. Analysis of the immune response to Hantaan virus nucleocapsid protein C-terminal-specific CD8(+) T cells in patients with hemorrhagic fever with renal syndrome. Viral Immunol 2009; 22:253-60.
61. Kaukinen P, Vaheri A, Plyusnin A. Hantavirus nucleocapsid protein: a multifunctional molecule with both housekeeping and ambassadorial duties. Arch Virol 2005; 150:1693-713. (Pubitemid 41176630)
62. Sen N, Sen A, Mackow ER. Degrons at the C terminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation. J Virol 2007; 81:4323-30. (Pubitemid 46586926)
63. Safronetz D, Hegde NR, Ebihara H, Denton M, Kobinger GP, St JS, et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol 2009; 83:7285-95.
64. Manigold T, Martinez J, Lazcano X, Ye C, Schwartz S, Cuiza A, et al. Case report: T-cell responses during clearance of Andes virus from blood cells 2 months after severe hantavirus cardiopulmonary syndrome. J Med Virol 2008; 80:1947-51.
65. Dargeviciute A, Brus SK, Sasnauskas K, Kruger DH, Meisel H, Ulrich R, Lundkvist A. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. Vaccine 2002; 20:3523-31. (Pubitemid 35248076)
66. Ulrich R, Lundkvist A, Meisel H, Koletzki D, Sjolander KB, Gelderblom HR, et al. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine 1998; 16:272-80. (Pubitemid 27521010)
67. Schonrich G, Rang A, Lutteke N, Raftery MJ, Charbonnel N, Ulrich RG. Hantavirus-induced immunity in rodent reservoirs and humans. Immunol Rev 2008; 225:163-89.
68. + T cells trigger capillary leakage in viral hemorrhagic fevers? Immunol Lett 2007; 113:117-20.
69. Wang M, Wang J, Zhu Y, Xu Z, Yang K, Yang A, Jin B. Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis 2009; 199:188-95.
70. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000; 18:275-308. (Pubitemid 30365382)
71. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91. (Pubitemid 32368030)
72. Makela S, Mustonen J, Ala-Houhala I, Hurme M, Partanen J, Vapalahti O, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J Infect Dis 2002; 186:843-6. (Pubitemid 35013439)
73. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, Vaheri A. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int 1996; 49:217-21. (Pubitemid 26024237)
74. Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines 2002; 1:373-84. (Pubitemid 36559872)
75. Maes P, Clement J, Van RM. Recent approaches in hantavirus vaccine development. Expert Rev Vaccines 2009; 8:67-76.
76. Schmaljohn C. Vaccines for hantaviruses. Vaccine 2009; 27:61-4.
77. Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis 2010; 16:1195-203.
78. Boudreau E, Sellers K, Rusnak J, Rivard R, Bovnzi D, Joselyn M, et al. Phase 1 clinical study on the safety, tolerability and immunogenicity of Hantaan and Puumala DNA vaccines. Abstracts of the VIII International Conference on HFRS HPS and Hantavirus, Athens, Greece 2010; 83.
79. Li D. Trends of HFRS epidemiology and the expanded program on immunization with hantavirus vacccines in China. Abstracts of the VIII International Conference on HFRS HPS and Hantavirus, Athens, Greece 2010; 82.
80. Abu Daude NH, Kariwa H, Tkachenko E, Dzagurova T, Medvedkina O, Tkachenko P, et al. Genetic and antigenic analyses of a Puumala virus isolate as a potential vaccine strain. Jpn J Vet Res 2008; 56:151-65.
81. Handke W, Oelschlegel R, Franke R, Wiedemann L, Kruger DH, Rang A. Generation and characterization of genetic reassortants between Puumala and Prospect Hill hantavirus in vitro. J Gen Virol 2010; 91:2351-9.
82. Yuan ZG, Li XM, Mahmmod YS, Wang XH, Xu HJ, Zhang XX. A single immunization with a recombinant canine adenovirus type 2 expressing the seoul virus Gn glycoprotein confers protective immunity against seoul virus in mice. Vaccine 2009; 27:5247-51.
83. Yuan ZG, Luo SJ, Xu HJ, Wang XH, Li J, Yuan LG, He LT, Zhang XX. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences. J Gen Virol 2010; 91:1764-71.
84. Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 1998; 50:141-82.
85. Li C, Liu F, Liang M, Zhang Q, Wang X, Wang T, et al. Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine 2010; 28:4294-300.
86. Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77:481-8. (Pubitemid 36004987)
87. Huggins JW, Kim GR, Brand OM, McKee KT Jr. Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis 1986; 153:489-97. (Pubitemid 16135652)
88. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119-27.
89. Rusnak JM, Byrne WR, Chung KN, Gibbs PH, Kim TT, Boudreau EF, et al. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res 2009; 81:68-76.
90. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4:211-9. (Pubitemid 30058021)
91. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39:1307-13. (Pubitemid 39458516)
92. Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, et al. Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res 2008; 79:19-27.
93. Chung DH, Strouse JJ, Sun Y, Arterburn JB, Parker WB, Jonsson CB. Synthesis and anti-Hantaan virus activity of N(1)-3-fluorophenyl-inosine. Antiviral Res 2009; 83:80-5.
94. Hall PR, Malone L, Sillerud LO, Ye C, Hjelle BL, Larson RS. Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des 2007; 69:180-90. (Pubitemid 46608456)
95. Larson RS, Brown DC, Ye C, Hjelle B. Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor. J Virol 2005; 79:7319-26. (Pubitemid 40756767)
96. Hall PR, Hjelle B, Brown DC, Ye C, Bondu-Hawkins V, Kilpatrick KA, Larson RS. Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade. Antimicrob Agents Chemother 2008; 52:2079-88. (Pubitemid 351758545)
97. Hall PR, Leitao A, Ye C, Kilpatrick K, Hjelle B, Oprea TI, Larson RS. Small molecule inhibitors of hantavirus infection. Bioorg Med Chem Lett 2010; 20:7085-91.
98. Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res 2008; 78:162-9.
99. Groen J, Gerding M, Koeman JP, Roholl PJ, van Amerongen G, Jordans HG, et al. A macaque model for hantavirus infection. J Infect Dis 1995; 172:38-44.
100. Sironen T, Klingstrom J, Vaheri A, Andersson LC, Lundkvist A, Plyusnin A. Pathology of Puumala hantavirus infection in macaques. PLoS ONE 2008; 3:3035.
101. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289:6-14. (Pubitemid 33016232)